Literature DB >> 11886422

Hypersensitivity reaction to intravitreal clindamycin therapy.

Peter Kim1, Nancy Younan, Minas T Coroneo.   

Abstract

A Caucasian woman presenting with recurrence of intra-ocular toxoplasmosis was given intravitreal clindamycin. She subsequently developed a hypersensitivity reaction in the form of a generalized erythematous rash. To the authors' knowledge, hypersensitivity reactions to an antibiotic given by the intra-vitreal route have not previously been reported.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11886422     DOI: 10.1046/j.1442-6404.2002.00502.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  5 in total

Review 1.  [Ocular side effects and complications of intravitreal triamcinolone acetonide injection].

Authors:  G B Jaissle; P Szurman; K U Bartz-Schmidt
Journal:  Ophthalmologe       Date:  2004-02       Impact factor: 1.059

2.  Safety of intravitreal clindamycin in albino rabbit eyes.

Authors:  Zohar Habot-Wilner; Orit Mazza; Jonathan Shahar; Amir Massarweh; Irit Mann; Anat Loewenstein; Ido Perlman
Journal:  Doc Ophthalmol       Date:  2017-07-25       Impact factor: 2.379

3.  Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series.

Authors:  Lalit Verma; Mithun Thulasidas; Avnindra Gupta
Journal:  Clin Ophthalmol       Date:  2020-12-07

4.  Characterizing the network of drugs and their affected metabolic subpathways.

Authors:  Chunquan Li; Desi Shang; Yan Wang; Jing Li; Junwei Han; Shuyuan Wang; Qianlan Yao; Yingying Wang; Yunpeng Zhang; Chunlong Zhang; Yanjun Xu; Wei Jiang; Xia Li
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

Review 5.  Current treatment of toxoplasma retinochoroiditis: an evidence-based review.

Authors:  Meredith Harrell; Petros E Carvounis
Journal:  J Ophthalmol       Date:  2014-08-13       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.